Linagliptin + Empagliflozin placebo + linagliptin placebo low dose + Empagliflozin + linagliptin low dose + Linagliptin placebo + Empagliflozin + linagliptin high dose + Empa + lina highdose placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2
Trial Timeline
May 14, 2015 → Mar 27, 2017
NCT ID
NCT02453555About Linagliptin + Empagliflozin placebo + linagliptin placebo low dose + Empagliflozin + linagliptin low dose + Linagliptin placebo + Empagliflozin + linagliptin high dose + Empa + lina highdose placebo
Linagliptin + Empagliflozin placebo + linagliptin placebo low dose + Empagliflozin + linagliptin low dose + Linagliptin placebo + Empagliflozin + linagliptin high dose + Empa + lina highdose placebo is a phase 3 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT02453555. Target conditions include Diabetes Mellitus, Type 2.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus, Type 2 were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02453555 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 2